Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

Double blind protocol treatment of 2/3 of the patients with omalizumab and 1/3 placebo administer for 4 months. Patients selected for the study must have both aspirin exacerbated

aspirin
rhinitis
omalizumab
respiratory disorder
allergic asthma
  • 37 views
  • 07 Nov, 2020
  • 1 location
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies

  • 9 views
  • 26 Jan, 2021
  • 13 locations
Cholinergic Urticaria - Efficacy of Dupilumab

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).

  • 52 views
  • 23 Jan, 2021
  • 3 locations
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil

The anti-interleukin-5 monoclonal antibody mepolizumab is approved as an add-on therapy in Europe, Canada, USA, and other countries, to standard of care for the treatment of patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbation rates and dependency on oral corticosteroid use in clinical trials in patients …

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are na ve to Intolerant of or Incomplete Responders to Omalizumab

Primary Objective: To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A: omalizumab nave; Study B

corticosteroids
urticaria
dupilumab
h1 antihistamine
antihistamines
  • 10 views
  • 27 Jan, 2021
  • 79 locations
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

better efficacy over omalizumab. The study population will consist of approximately 1050 male and female subjects aged 12 years who have been diagnosed with CSU and who remain symptomatic despite

urticaria
antihistamines
a 12
ligelizumab
omalizumab
  • 539 views
  • 27 Jan, 2021
  • 164 locations
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

better efficacy over omalizumab. The study population will consist of approximately 1050 male and female subjects aged 12 years who have been diagnosed with CSU and who remain symptomatic despite

urticaria
antihistamines
a 12
ligelizumab
omalizumab
  • 614 views
  • 27 Jan, 2021
  • 196 locations
Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

The goal of this study is to examine the mechanism of action of omalizumab in ex vivo tissue culture of whole human nasal polyps from patients with chronic rhino sinusitis with nasal polyposis

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)

Food allergy is a common disease in childhood affecting up to 8% of children in Westernized countries. About 30 percent of children with food allergies are allergic to more than one food, most often milk, egg, wheat, peanut and tree nut. Peanut and hazelnut are common triggers of severe and …

omalizumab
anaphylaxis
xolair
allergen
  • 0 views
  • 25 Jan, 2021
  • 1 location
Omalizumab to Accelerate a Symptom-driven Multi-food OIT

This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at

  • 6 views
  • 26 Jan, 2021
  • 6 locations